ACTRN12618000811202
Active, not recruiting
Phase 3
Targeted thromboprophylaxis in ambulatory patients receiving anticancer therapies for lung or gastrointestinal cancers: an investigator-initiated, open-label, multicentre, randomised, phase 3 trial (TARGET-TP)
Peter MacCallum Cancer Centre0 sites328 target enrollmentMay 11, 2018
ConditionsCancer - Oesophageal (gullet)Cancer - StomachThromboembolismLung CancerBowel CancerPancreatic CancerLiver CancerOesophageal CancerStomach CancerCancer - Lung - Non small cellCancer - Lung - Small cellCancer - Bowel - AnalCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - Bowel - Small bowel (duodenum and ileum)Cancer - PancreaticCancer - Liver
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Cancer - Oesophageal (gullet)
- Sponsor
- Peter MacCallum Cancer Centre
- Enrollment
- 328
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patient is 18 years of age or older
- •2\.Patient has a confirmed histological diagnosis of any gastrointestinal or lung cancer
- •3\.Patient is newly diagnosed treatment\-naïve or is previously treated with newly relapsed or progressive disease
- •4\.Patient is being considered for, but has not commenced anticancer therapy including chemotherapy and/or radiotherapy and/or immunotherapy and/or targeted therapies, within neoadjuvant, adjuvant, curative, or palliative treatment settings
- •5\.Patient has expected life expectancy of at least six months, as estimated by their treating clinician
- •6\.Patient has provided written confirmation of informed consent on participant information and consent form
Exclusion Criteria
- •1\.Patients who have already commenced anticancer therapy
- •2\.Patients with a clinical indication for therapeutic anticoagulation (antiplatelet agents such as clopidogrel and aspirin are permitted)
- •3\.Patients with a contraindication to anticoagulation and/or specifically low molecular weight heparin
- •4\.Cancer diagnosis other than those specified in inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Thromboprophylaxis in patients with moderate COVID-19COVID-19JPRN-UMIN000046519Port said University124
Recruiting
Phase 1
Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosisThromboprophylaxis in good and intermediate prognosis advanced germ cell tumorsMedDRA version: 20.0Level: LLTClassification code: 10075819Term: Testicular germ cell tumor Class: 10029104Therapeutic area: Diseases [C] - Male Urogenital Diseases [C12]Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2022-502426-41-00Institut Gustave Roussy387
Not yet recruiting
Phase 4
Prophylaxis of venous thromboembolism in patients with a fracture of the lower extremity being treated conservatively with a below-knee plaster cast.pulmonary embolismthrombosis10014523NL-OMON39940Vrije Universiteit Medisch Centrum670
Completed
Not Applicable
Thrombosis Prevention TrialISRCTN63594484Sponsor not defined - Record provided by the Medical Research Council (UK)5,499
Not yet recruiting
Not Applicable
Efficacy and safety of Thromboprophylaxis in Critically Ill Medical Patients: A Prospective, single centre studyvenous thromboembolismDeep vein thrombosisPulmonary embolismcritical illnessvenous thromboembolismDeep vein thrombosisPulmonary embolismpharmacological thromboprophylaxismechanical thromboprophylaxisTCTR20230927002Faculty of Medicine, Chiang Mai University462